Expansion of services in Rwanda is underway, including a nationally approved diagnostic and treatment protocol for CML, a national scale-up of cancer programs, expansion of the imatinib-procurement process through GIPAP, and diversification of in-country testing via Xpert BCR-ABL Monitor. This evidence concerns the gene ABL1 and cancer.